Home Cart Sign in  
Chemical Structure| 53179-13-8 Chemical Structure| 53179-13-8

Structure of Pirfenidone
CAS No.: 53179-13-8

Chemical Structure| 53179-13-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pirfenidone is an antifibrotic drug that inhibits TGF-β1 and other fibrosis-related factors. Pirfenidone is mainly used for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases.

Synonyms: AMR69; S-7701; Pirfenex

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pirfenidone

CAS No. :53179-13-8
Formula : C12H11NO
M.W : 185.22
SMILES Code : C1=CC=CC=C1N2C(C=CC(=C2)C)=O
Synonyms :
AMR69; S-7701; Pirfenex
MDL No. :MFCD00866047
InChI Key :ISWRGOKTTBVCFA-UHFFFAOYSA-N
Pubchem ID :40632

Safety of Pirfenidone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • TGF-β

In Vitro:

Cell Line
Concentration Treated Time Description References
4T1 breast cancer cells 0.1 μg/mL 6, 24, and 48 h To test the effect of Pirfenidone/m on mitochondrial activity of 4T1 breast cancer cells, showing no cytotoxicity ACS Nano. 2023 Dec 26;17(24):24654-24667.
MLE-12 cells 100 μM 3 h To evaluate the effect of Pirfenidone on MAVS expression, results showed that Pirfenidone failed to reduce MAVS expression. Eur Respir J. 2021 Apr 15;57(4):2000652.
HFL-1 cells 1.5 mg/mL 48 h To investigate the inhibitory effect of Pirfenidone on TGF β1-induced fibroblast differentiation. The results showed that Pirfenidone significantly inhibited TGF β1-induced a-SMA expression in a dose-dependent manner. iScience. 2023 Apr 6;26(5):106586.
Human bronchial epithelial cells (HBE) 1 mM, 500 µM, 100 µM 24 h To evaluate the effect of Pirfenidone on the expression of NOX4 and antioxidant genes in HBE cells from IPF patients. The results showed that Pirfenidone significantly reduced NOX4 expression and induced the expression of antioxidant genes in some patients. 2023 Feb 10;12(2):443. doi: 10.3390/antiox12020443.
Pancreatic acinar cells 0.5 mg/mL 30 min To evaluate the effect of Pirfenidone on trypsin activation, results showed that Pirfenidone was unable to inhibit carbachol-induced trypsin activation. JCI Insight. 2022 Jan 25;7(2):e141108.
Pancreatic acinar cells 0.5 mg/mL 4 h To evaluate the effect of Pirfenidone on cytokine secretion, results showed that Pirfenidone pretreatment reduced the secretion of TNF-α and IL-6. JCI Insight. 2022 Jan 25;7(2):e141108.
Macrophages 0.5 mg/mL 24 h To evaluate the effect of Pirfenidone on macrophage polarization, results showed that Pirfenidone significantly reduced the secretion of M1 markers TNF-α and IL-6 and increased the expression of M2 markers IL-10, IL-4, and Arginase-1. JCI Insight. 2022 Jan 25;7(2):e141108.
Th17 cells 10 µM 3 days To evaluate the effect of Pirfenidone on Th17 differentiation, results showed that Pirfenidone significantly inhibited IL-17A secretion at 10 µM. Cells. 2023 Dec 8;12(24):2795.
pancreatic acinar cells 0.5 mg/mL 30 min To evaluate the effect of Pirfenidone on trypsin activation in pancreatic acinar cells, results showed that Pirfenidone was unable to inhibit carbachol-induced trypsin activation JCI Insight. 2022 Jan 25;7(2):e141108.
pancreatic acinar cells 0.5 mg/mL 1 h To evaluate the effect of Pirfenidone on trypsin activation in pancreatic acinar cells, results showed that Pirfenidone was unable to inhibit carbachol-induced trypsin activation JCI Insight. 2022 Jan 25;7(2):e141108.
NCI-H460 cells 2.0 mM 48 h To evaluate the effect of Pirfenidone combined with Paclitaxel on the growth of NCI-H460 cells, results showed that the combined treatment significantly reduced cell growth. Int J Mol Sci. 2022 Mar 26;23(7):3631.
A549 cells 1.5 mM 48 h To evaluate the effect of Pirfenidone combined with Paclitaxel on the growth of A549 cells, results showed that the combined treatment had a clear cytotoxic effect, but it was not statistically significant compared to individual treatments. Int J Mol Sci. 2022 Mar 26;23(7):3631.
NCI-H322 cells 2 mM 48 h To evaluate the effect of Pirfenidone combined with Paclitaxel on the growth of NCI-H322 cells, results showed that the combined treatment had a clear cytotoxic effect, but it was not statistically significant compared to individual treatments. Int J Mol Sci. 2022 Mar 26;23(7):3631.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Bleomycin-induced pulmonary fibrosis model Oral administration 100 mg/kg Once daily for 21 days To evaluate the antifibrotic activity of Pirfenidone in a bleomycin-induced pulmonary fibrosis model, the results showed that Pirfenidone significantly alleviated pathological damage and collagen deposition in pulmonary fibrosis. Acta Pharm Sin B. 2023 Feb;13(2):722-738.
Mice 4T1 and E0771 triple negative breast tumor models and MCA205 fibrosarcoma model Intravenous injection 5 or 10 mg/kg Once daily for 5 days To test the effect of Pirfenidone/m on tumor microenvironment modulation, showing effective reduction in tumor stiffness, improved perfusion, and significant delay in primary tumor growth ACS Nano. 2023 Dec 26;17(24):24654-24667.
Mice Pulmonary fibrosis model Intraperitoneal injection 40 mg/kg Every 2 days until day 21 To evaluate the therapeutic effect of Pirfenidone on pulmonary fibrosis, results showed that the therapeutic effects of Pirfenidone were not related to MAVS signaling. Eur Respir J. 2021 Apr 15;57(4):2000652.
C57BL/6 mice Bleomycin-induced pulmonary fibrosis model Intraperitoneal injection 100 mg/kg Once daily for 14 days To investigate the therapeutic effect of Pirfenidone on bleomycin-induced pulmonary fibrosis. The results showed that Pirfenidone significantly improved lung structure, reduced collagen deposition, and significantly downregulated the mRNA levels of FN. iScience. 2023 Apr 6;26(5):106586.
Mice Acute pancreatitis model Oral gavage 400 mg/kg Multiple doses, duration varies depending on the experimental model To evaluate the therapeutic effect of Pirfenidone in acute pancreatitis models, results showed that Pirfenidone significantly reduced inflammation and injury in the pancreas and lungs. JCI Insight. 2022 Jan 25;7(2):e141108.
Balb/c mice Bleomycin-induced pulmonary fibrosis model Oral 150 mg/kg 6 times per week for 2 weeks To evaluate the therapeutic effect of Pirfenidone on bleomycin-induced pulmonary fibrosis, results showed that Pirfenidone improved lung function and reduced fibrotic changes. Cells. 2023 Dec 8;12(24):2795.
Mice Acute pancreatitis model Oral gavage 400 mg/kg Once daily for 2 days To evaluate the effect of Pirfenidone in the treatment of acute pancreatitis models, results showed that Pirfenidone could alleviate inflammation and injury in the pancreas and lungs JCI Insight. 2022 Jan 25;7(2):e141108.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03208933 Idiopathic Pulmonary Fibrosis PHASE3 COMPLETED 2019-11-13 Regional State Budgetary Insti... More >>tution of Healthcare "Regional Cinilcal Hospital"; Pulmonology, Barnaul, Altaj, 656024, Russian Federation|GBUZ Regional clinical hospital #4, Chelyabinsk, Evenkija, Russian Federation|SBEI HPE "The First St.Petersburg State Medical University n.a. acad. I.P.Pavlova"of MoH of RF, Sankt-peterburg, Leningrad, 197022, Russian Federation|Central NII tuberkuleza RAMN, Moscow, Moskovskaja Oblast, Russian Federation|Pulmonologii NII FMBA of Russia, Moscow, Moskovskaja Oblast, Russian Federation|New Hospital, Yekaterinburg, Sverdlovsk, Russian Federation|I.M. Sechenov First Moscow State Medical University: The E.M. Tareyev Clinic, Moscow, 119992, Russian Federation|Vladimirskiy Regional Scientific Research Inst., Moscow, 129110, Russian Federation|State Novosibirsk Regional Clinical Hospital, Novosibirsk, 630087, Russian Federation|Republican clinical hospital named after G.G. Kuvatov, UFA, 450005, Russian Federation|Budget Institution of Healthcare of Voronezh Region "Voronezh Regional Clinical Hospital #1", Voronezh, 394066, Russian Federation Less <<
NCT02525484 Healthy Volunteer PHASE1 COMPLETED 2025-08-15 Merritt Island, Florida, 32953... More >>, United States Less <<
NCT02821689 Dermatopolymyositis|Interstiti... More >>al Lung Disease Less << PHASE4 UNKNOWN 2025-06-18 Department of Rheumatology, Re... More >>n Ji Hospital South Campus, School of Medicine, Shanghai JiaoTong University, Shanghai, Shanghai, 200001, China Less <<
NCT00332033 Uterine Leiomyoma|Fibroids PHASE2 COMPLETED 2007-02-16 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT00001959 Fibrosis|Focal Glomerulosclero... More >>sis|Kidney Failure|Nephrotic Syndrome|Proteinuria Less << PHASE2 COMPLETED 2025-10-08 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT00754780 Neurofibromatosis PHASE2 COMPLETED - -
NCT00011076 Hypertrophic Cardiomyopathy PHASE2 COMPLETED 2025-04-03 National Heart, Lung and Blood... More >> Institute (NHLBI), Bethesda, Maryland, 20892, United States Less <<
NCT03359863 Restrictive Chronic Lung Allog... More >>raft Dysfunction|Lung Transplant Rejection Less << PHASE2 COMPLETED 2021-10-28 University of California, San ... More >>Francisco, San Francisco, California, 94143, United States Less <<
NCT00063583 Diabetes Mellitus|Diabetic Nep... More >>hropathy Less << PHASE1|PHASE2 COMPLETED 2025-03-09 National Institute of Diabetes... More >> and Digestive and Kidney Disease (NIDDK), Bethesda, Maryland, 20892, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|The Center for Diabetic Kidney Disease at Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States Less <<
NCT02408744 Fibrosis|Chronic Kidney Diseas... More >>e Less << PHASE1|PHASE2 COMPLETED 2025-09-13 -
NCT00076102 Neurofibromatosis 1|Neurofibro... More >>ma, Plexiform Less << PHASE2 COMPLETED 2010-04-01 University of Alabama, Birming... More >>ham, Alabama, 35233, United States|Childrens National Medical Center, Washington, District of Columbia, 20010, United States|Childrens Memorial Hospital, Chicago, Chicago, Illinois, 60614, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, 21287, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States|Childrens Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Mayo Clinic, Rochester, Rochester, Minnesota, 55905, United States|St. Louis Children's Hospital, Saint Louis, Missouri, 63110, United States|Beth Israel Medical Center, New York, New York, 10003, United States|SUNY Upstate Medical University, Syracuse, New York, 13210, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Oregon Health Sciences University, Portland, Oregon, 97201-3098, United States|Childrens Hospital, Philadelphia, Philadelphia, Pennsylvania, 19104, United States|Childrens Hospital, Pittsburgh, Pittsburgh, Pennsylvania, 15213, United States|Texas Children's Hospital, Houston, Texas, 77030, United States Less <<
NCT02296281 Radiation Pneumonitis PHASE2 UNKNOWN - -
NCT02699879 Idiopathic Pulmonary Fibrosis COMPLETED 2016-09-15 Medical University Graz; Depar... More >>tment for Respiratory Diseases, Graz, 8036, Austria|LKH Hohenems; Abteilung für Pulmologie, Hohenems, 6845, Austria|Medizinische Universitat Innsbruck; Department of Internal Medicine, Pneumology Centre, Innsbruck, 6020, Austria|Klinikum Klagenfurt; Abteilung für Pulmologie, Klagenfurt, 9020, Austria|St. Johanns-Spital; Abt. Für Lungenkrankungen, Salzburg, 5020, Austria|Aarhus University Hospital; Lungemed afd. B, Aarhus, 8000, Denmark|Gentofte Hospital, Lungemedicinsk Afdeling, Hellerup, 2900, Denmark|Odense Universitetshospital, Lungemedicinsk Afdeling J, Odense, 5000, Denmark|Helsinki University Central Hospital; Dep. of Pulmonary Medicine, Helsinki, 00290, Finland|Kuopio University Hospital, Kuopio, 70211, Finland|Tampere University Hospital; Lung Clinic, Tampere, 33521, Finland|Turku University Hospital; Dept of Pulmonology, Turku, 20521, Finland|CHU Angers,Service de Pneumologie, Angers, 49933, France|Hopital Jean Minjoz; Pneumologie, Besancon, 25030, France|Hopital Avicenne; Pneumologie, Bobigny, 93000, France|Hopital de La Cavale Blanche; Service de Medecine Interne & de Pneumologie, Brest, 29609, France|Hopital Louis Pradel; Pneumologie, Bron, 69677, France|Hopital Cote De Nacre; Pneumologie, Caen, 14033, France|Chu Site Du Bocage;Pneumologie, Dijon, 21079, France|CHU de Grenoble; Medecine Aigue Spec, Grenoble, 38043, France|Hopital Calmette; Pneumologie, Lille, 59037, France|CHU de Limoges, Limoges, 87042, France|Hopital Nord; Pneumologie, Marseille cedex 20, 13915, France|Hopital Nord AP-HM, Marseille, 13015, France|CHU Montpellier, Montpellier, 34295, France|Hopital Saint Louis, Paris, 75475, France|Hopital Bichat Claude Bernard ; Service de Pneumologie, Paris, 75877, France|HEGP; Pneumologie, Paris, 75908, France|Hopital Tenon;Pneumologie, Paris, 75970, France|H?pital Haut-Lévêque - CHU de Bordeaux - Groupe Hospitalier Sud, Pessac, 33604, France|Hopital De La Maison Blanche;Maladies Respiratoires, Reims, 51092, France|Hopital de Pontchaillou; Service de Pneumologie, Rennes, 35033, France|Chu De Strasbourg; Hopital Civil, Strasbourg, 67091, France|Hopital Larrey; Pneumologie, Toulouse, 31059, France|Chu De Tours,Service de Pneumologie, Tours, 37000, France|Zentralklinik Bad Berka GmbH; Pneumologie, Bad Berka, 99437, Germany|Lungenklinik Ballenstedt/Harz gGmbH Lungenklinik Ballenstedt/Harz gGmbH, Ballenstedt, 06493, Germany|Evang. Lungenklinik Berlin Klinik für Pneumologie, Berlin, 13125, Germany|Charite - Universit?tsmedizin Berlin; Campus Virchow-Klinikum, Med. Klinik m. S. Infekt und Pneumo, Berlin, 13353, Germany|Gemeinschaftskrankenhaus Havelh?he Klinik f.Innere Medizin Kardiologie Pneumologie, Berlin, 14089, Germany|HELIOS Klinikum Emil von Behring Klinik f.Pneumologie Onkologie u.Infektiologie, Berlin, 14165, Germany|Berufsgenossenschaftliches Uni-Klinikum Bergmannsheil GmbH, Bochum, 44789, Germany|Klinkum Coburg GmbH, Coburg, 96450, Germany|Fachkrankenhaus Coswig GmbH Zentrum f.Pneumologie Beatmungsmedizin Thorax-u.Gef??chirurgie, Coswig, 01640, Germany|Carl-Thiem-Klinik Cottbus; Medizinische Klinik, Cottbus, 03048, Germany|Klinik Donaustauf Zentrum für Pneumologie, Donaustauf, 93093, Germany|Ruhrlandklinik Lungenzentrum der UNI Essen Abt.Pneumologie-Allergologie, Essen, 45239, Germany|Klinikum Esslingen; Klinik für Kardiologie, Angiologie und Pneumologie, Esslingen, 73730, Germany|IFS - Interdisziplin?res Facharztzentrum; Institut für klinische Forschung Pneumologie, Frankfurt am Main, 60596, Germany|Klinik Maingau, Frankfurt, 60318, Germany|Studienzentrum/Praxis Dr. Keller Frankfurt, Frankfurt, 60389, Germany|Universit?tsklinikum Freiburg, Abteilung Pneumologie, Freiburg, 79106, Germany|Klinik Schillerh?he Zentrum f.Pneumologie u.Thoraxchirurgie, Gerlingen, 70839, Germany|Universit?tsklinikum Standort Gie?en Medizinische Klinik II u. Poliklinik Innere Med./Pneumologie, Gie?en, 35392, Germany|Universit?tsmedizin Greifswald Klinik für Innere Medizin B und Poliklinik, Greifswald, 17489, Germany|LungenClinic Grosshansdorf GmbH; Zentrum fur Pneumologie und Thoraxchirurgie, Gro?hansdorf, 22927, Germany|Medizinische Hochschule Hannover, Hannover, 30625, Germany|KRH Klinikum Oststadt-Heidehaus; Pneumologie, Intensiv- und Schlafmedizin, Hannover, 30659, Germany|Lungenklinik Hemer; Abt. Pneumologie, Hemer, 58675, Germany|Universitaetsklinikum des Saarlandes; Innere Medizin V, Homburg/Saar, 66421, Germany|Fachklinik für Lungenerkrankungen, Immenhausen, 34376, Germany|Universit?tsklinikum Jena; Medizinische Klinik I, Jena, 07747, Germany|Universitaetsklinikum Schleswig-Holstein, Campus Kiel, Kiel, 24116, Germany|Universit?t Leipzig; Medizinische Klinik und Poliklinik I, Abteilung Pneumologie, Leipzig, 04103, Germany|Lungenklinik Lostau gGmbH; Klinik für Pneumologie II, Lostau, 39291, Germany|Klinik L?wenstein gGmbH Medizinische Klinik II, L?wenstein, 74245, Germany|Universit?tsklinikum Magdeburg Klinik für Kardiologie Angiologie u.Pneumologie, Magdeburg, 39120, Germany|Klinikum der Universit?t München; Campus Gro?hadern; Med. Klinik und Poliklinik V, München, 81377, Germany|Klinikum Nuernberg Nord; Medizinische Klinik 3, Schwerpunkt Pneumologie, Allergologie, Schlafmedizin, Nürnberg, 90419, Germany|RoMed Klinikum Rosenheim, Medizinische Klinik III, Rosenheim, 83022, Germany|Krankenhaus Bethanien gGmbH, Solingen, 42699, Germany|Krankenhaus vom Roten Kreutz; Klinik fuer Pneumologie, Stuttgart, 70372, Germany|Johanniter-Krankenhaus im Fl?ming Treuenbrietzen GmbH; Fachklinik Pneumologie/ Thoraxchirurgie, Treuenbrietzen, 14929, Germany|Fachkliniken Wangen Medizinische Klinik, Wangen, 88239, Germany|Universit?tsklinikum Würzburg, Kinderklinik u. Poliklinik, Wuerzburg, 97080, Germany|Cork University Hospital, Cork, Ireland|St Vincents University Hospital, Dublin 4, Ireland|Mater Misecordiae University Hospital, Dublin, 7, Ireland|Galway University Hospital; Department of Respiratory Medicine, Galway, Ireland|Ospedale Morgagni-Pierantoni; U.O. Pneumologia, Forlì, Emilia-Romagna, 47121, Italy|A.O. Universitaria Policlinico Di Modena; DIP. Malattie Dell'apparato Respiratorio, Modena, Emilia-Romagna, 41124, Italy|Universita' Degli Studi Di Milano Bicocca, Ospedale Vecchio; facolta di medicina e chirurgia, dipart, Monza, Lombardia, 20052, Italy|A.O. Universitaria San Luigi Gonzaga di Orbassano; Ambulatorio per le Malattie Rare del Polmone, Orbassano (TO), Piemonte, 10043, Italy|Azienda Ospedaliero Universitaria Di Sassari; Clinica Pneumologica, Sassari, Sardegna, 07100, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Toscana, 50141, Italy|A.O. Univ. Senese Policlinico S. Maria alle Scotte; UOC Malattie Resepiratorie e Trapianto Polmonare, Siena, Toscana, 53100, Italy|Haukeland Hospital - University Of Bergen: Department of Resp Med, Bergen, 5021, Norway|Oslo University Hospital Rikshospitalet; Lungeavdelingen, Oslo, 0424, Norway|St. Olav's Hospital; Lung Clinic, Trondheim, 7006, Norway|Karolinska Universitetssjukhuset Solna; Lung Allergikliniken, Stokholm, Solna, 17176, Sweden|Akademiska Sjukhuset; Lungmedicinska Kliniken, Uppsala, 751 85, Sweden|Southmead Hospital; Respiratory Department, Bristol, BS10-5NB, United Kingdom|Papworth Hospital NHS Foundation Trust; Respiratory Department, Cambridge, CB23 3RE, United Kingdom|Castle Hill Hospital; Respiratory Medicine, Cottingham, HU16 5JQ, United Kingdom|Royal Devon and Exeter Hospital (Wonford), Exeter, EX2 5DW, United Kingdom|Southampton General Hospital; Respiratory Department, Hampshire, SO16 6YD, United Kingdom|Glenfield Hospital, Leicester, LE3 9QP, United Kingdom|University Hospital Aintree; Pulmonary Vascular Diseases Unit, Liecester, L9 7AL, United Kingdom|University College London Hospital; Respiratory Medicine, London, NW1 2BU, United Kingdom|Royal Brompton Hospital; Respiratory Department, London, SW3 6NP, United Kingdom|St. Mary'S Hospital; Dept of Medicine, London, W2 1NY, United Kingdom|Wythenshawe Hospital, Manchester, M23 9QZ, United Kingdom|Nottingham University Hospitals City Campus, Nottingham, NG5 1PB, United Kingdom|Queen Alexandra Hospital; Respiratory Centre, Portsmouth, PO6 3LY, United Kingdom|Northern General Hospital, Sheffield, S5 7AU, United Kingdom|University Hospital of North Staffordshire; ILD Clinic, Stoke-on-Trent, ST4 6QG, United Kingdom Less <<
NCT01933334 Systemic Sclerosis PHASE2 COMPLETED 2025-09-14 Mayo Clinic, Scottsdale, Scott... More >>sdale, Arizona, 85259, United States|University of California, Los Angeles, Los Angeles, California, 90095, United States|Stanford University School of Medicine, Redwood City, California, 94063, United States|University of California, San Francisco, San Francisco, California, 94143, United States|National Jewish Medical and Research Center, Denver, Colorado, 80206, United States|Georgetown University Hospital, Washington, District of Columbia, 20007, United States|Northwestern University, Chicago, Chicago, Illinois, 60611, United States|Boston University Medical Center, Boston, Massachusetts, 02118, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Hospital for Special Surgery, New York, New York, 10021, United States|Columbia University, New York, New York, 10032, United States|University of Cincinnati, Cincinnati, Ohio, 45267, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|University of Toledo, Toledo, Ohio, 43614, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15261, United States|Medical University South Carolina, Charleston, South Carolina, 29425, United States|University of Texas, Houston, Houston, Texas, 77030, United States|University of Utah, Salt Lake City, Utah, 84132, United States|St. Joseph's Healthcare, Hamilton, Ontario, L8N 142, Canada|Toronto General Hospital, Toronto, Ontario, M5T 3L9, Canada|Università di Torino, Orbassano, Turin, 10043, Italy|University of Florence, Firenze, 50139, Italy Less <<
NCT04193592 Hermansky Pudlak Syndrome|Inte... More >>rstitial Lung Disease Less << PHASE2 UNKNOWN 2022-12-31 Thomas Jefferson University, P... More >>hiladelphia, Pennsylvania, 19107, United States|Mayaguez Medical Center, Mayaguez, 00680, Puerto Rico Less <<
NCT04461587 Coal Workers' Pneumoconiosis (... More >>Complicated) Less << PHASE2 COMPLETED 2022-11-16 Pulmonary Research of Abingdon... More >>, LLC, Abingdon, Virginia, 24210, United States Less <<
NCT05826821 Heart Failure With Preserved E... More >>jection Fraction Less << COMPLETED 2020-04-29 Manchester University NHS Foun... More >>dation Trust, Manchester, United Kingdom Less <<
NCT05133453 Asbestosis NOT_YET_RECRUITING 2025-02-26 -
NCT03115619 Idiopathic Pulmonary Fibrosis COMPLETED 2020-01-10 Sotiria Hospital for Diseases ... More >>of the Chest, Academic Department of Pneumonology, Athens, 115 27, Greece|University General Hospital of Athens "Attikon", B' University Pulmonary Clinic, Chaidari, 124 62, Greece|University General Hospital of Heraklio, Pulmonary Clinic, Heraklio, 711 10, Greece|University General Hospital of Ioannina, Ioannina, 455 00, Greece|General University Hospital of Larisa; Pneumonology Clinic, Larissa, 413 34, Greece|General Hospital of Thessaloniki Papanikolaou; Uni Pneumonology Dept., Thessaloniki, 570 10, Greece|Papanikolaou Hospital; Pneumonology Clinic, Thessaloniki, 570 10, Greece Less <<
NCT03385668 Pulmonary Fibrosis PHASE2 COMPLETED 2020-07-24 Cochin Hospital, Paris, 75014,... More >> France Less <<
NCT02141087 Idiopathic Pulmonary Fibrosis APPROVED_FOR_MARKETING - -
NCT00080223 Idiopathic Pulmonary Fibrosis|... More >>Pulmonary Fibrosis Less << PHASE2 COMPLETED 2015-04-30 Phoenix, Arizona, 85006, Unite... More >>d States|Pomona, California, 91767, United States|San Jose, California, 95119, United States|New Haven, Connecticut, 06520, United States|Sarasota, Florida, 34239, United States|Atlanta, Georgia, 30322, United States|Kailua, Hawaii, 96734, United States|Lahaina, Hawaii, 96761, United States|Nampa, Idaho, 83686, United States|Elk Grove Village, Illinois, 60007, United States|Boston, Massachusetts, 02118, United States|West Roxbury, Massachusetts, 02132, United States|St. Louis, Missouri, 63110, United States|Huntington Station, New York, 11746, United States|New York, New York, 10016, United States|New York, New York, 10029-6574, United States|Rochester, New York, 14620, United States|Worthington, Ohio, 43085, United States|Portland, Oregon, 97220, United States|Portland, Oregon, 97227, United States|Lancaster, Pennsylvania, 17601, United States|Dallas, Texas, 75390-8503, United States|Houston, Texas, 77005, United States|San Antonio, Texas, 78229, United States|Provo, Utah, 84604, United States|Annandale, Virginia, 22003, United States|Bremerton, Washington, 98310 - 3349, United States Less <<
NCT05801133 Lung Cancer PHASE2 RECRUITING 2025-09-01 Hubei Cancer Hospital, Wuhan, ... More >>Hubei, 430079, China Less <<
NCT02622477 Idiopathic Pulmonary Fibrosis COMPLETED 2025-12-16 Praxis Dr. med. Mathias Rolke ... More >>und Dr. med. Peter Rückert, Aschaffenburg, 63739, Germany|Evang. Lungenklinik Berlin Klinik für Pneumologie, Berlin, 13125, Germany|Dr. med. Martin Hoster, Dr. Hans-G. Lange von Stocmeier, Michael Behn und w., Bochum, 44787, Germany|Praxis Dr. med. Wilhelm Ammenwerth, Bochum, 44787, Germany|Augusta Kranken-Anstalt gGmbH, Bochum, 44791, Germany|Fachkrankenhaus Coswig GmbH, Coswig, 01640, Germany|Klinikum Werra-Mei?ner GmbH, Eschwege, 37269, Germany|Ruhrlandklinik Lungenzentrum der UNI Essen Abt.Pneumologie-Allergologie, Essen, 45239, Germany|Universit?tsklinikum Freiburg, Abteilung Pneumologie, Freiburg, 79106, Germany|Klinikum Fulda gAG; Universit?tsmedizin Marburg, Campus Fulda, Fulda, 36043, Germany|Ev. Krankenhaus G?ttingen-Weende E.V., G?ttingen, 37075, Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II, Halle, 06120, Germany|Kliniken der Stadt K?ln gGmbH Krankenhaus Merheim, K?ln, 51109, Germany|Universit?tsklinikum Magdeburg Klinik für Kardiologie Angiologie u.Pneumologie, Magdeburg, 39120, Germany|Praxis Dr. med. Matthias Waltert, Muenster, 48145, Germany|Thoraxzentrum, Abt. Pneumologie, Münnerstadt, Germany|Facharztzentrum üBAG, Sonneberg, 96515, Germany Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.40mL

1.08mL

0.54mL

26.99mL

5.40mL

2.70mL

53.99mL

10.80mL

5.40mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.

References

 

Historical Records

Categories